Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Helicon CEO Peter Abrahamson On Exploiting Niche Markets In China: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Perth, Australia-based Helicon was established in 2003 to identify and exploit niche market opportunities in the specialty pharmaceutical and health care markets of China and North Asia. The company has licensed exclusive marketing rights for four products: Volplex, Collatamp, MedWrap with Microban and Recell. PharmAsia News' Australian bureau recently sat down with Helicon CEO Peter Abrahamson to discuss the company's business strategy in China.

You may also be interested in...

Stranded Pigs Rescued By NZ Biotech, Helicon SFDA Approval For Skin Regeneration Device, Arana Ramps Up R&D - Australia/New Zealand Roundup

Stranded New Zealand Pig Herd Could Offer Better Treatments For Diabetes

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts